15.43 USD
↗ 0.38 (2.52%)AT CLOSE (11:59 AM EDT)
NovoCure Limited Ordinary Shares
NVCRNASDAQ • USD
15.32
↘ 0.12 (0.75%)
POST MARKET (AS OF 06:00 PM EDT)
Post Market
AS OF 06:00 PM EDT
15.32
↘ 0.12 (0.75%)
Market: CLOSED
NVCR is currently priced at $15.43. The stock presents a bearish profile across the board: technical indicators signal "Sell" and our fundamental models agree with a "Sell" rating. Notable factors include a concerning Altman Z-Score in the distress zone, negative Return on Equity and a bullish Golden Cross on the moving averages. The stock looks compelling on valuation, with multiples below sector averages across P/E, P/B, and EV/EBITDA.
Technical & fundamental data as of Jun 26, 2026.
Open?$14.91
High?$15.63
Low?$14.90
Prev. Close?$15.05
Volume?3.3M
Avg. Volume?1.7M
VWAP?$15.27
Rel. Volume?1.97x
Bid / Ask
Bid?$15.11 × 1.0K
Ask?$15.65 × 100
Spread?$0.54
Midpoint?$15.38
Valuation & Ratios
Market Cap?1.8B
Shares Out?115.8M
Float?105.2M
Float %?90.8%
P/E Ratio?N/A
P/B Ratio?5.40
EPS?-$1.49
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis, and other products and technologies for the treatment of Glioblastoma, Non-small cell lung cancer, and Pancreatic cancer. Geographically, the company derives the majority of its revenue from the United States and the rest from Germany, Japan, and other markets.
Themes
Employees
1.6K
Market Cap
1.7B
Industry
SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
Website
Listed
2015-10-02
Address
NO. 4 THE FORUM
ST. HELIER,
Phone: 44 (0)15 3475 6700
ST. HELIER,
Phone: 44 (0)15 3475 6700
Technical OutlookSell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-1/3)
Medium-Term (Wave)?▼ Bearish(-1/3)
Short-Term (Ripple)?▲ Bullish(+2/3)
MA Alignment?Mixed
Full Technical Analysis →Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?23
Z-Score?7
Momentum?60
Short Sent.?55
Piotroski F-Score?3/9Weak
Altman Z-Score?0.63Distress
Confidence?61%Moderate
Short InterestHigh
Short % of Float?9.18%Elevated
Short Interest?9.7M
Days to Cover?6.0
Free Float105.2M
Avg Daily Volume1.6M
Settlement Date2026-06-15
Financial Health
Current Ratio?2.86Strong
Quick Ratio?2.66Strong
Cash Ratio?0.40Low
Debt/Equity?0.59Moderate
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score92/100
P/E?N/A▾
P/B?5.40FAIR▾
Peers100
S&P34
P/S?2.65CHEAP▾
Peers100
S&P55
P/FCF?N/A▾
EV/EBITDA?-11.3CHEAP▾
S&P97
EV/Sales?2.81CHEAP▾
Peers100
S&P63
Returns & Efficiency
ROE?-52.3%WEAK▾
S&P3
ROA?-22.0%WEAK▾
S&P3
Cash Flow & Enterprise
FCF?$-48072000
Enterprise Value?$1.9B
Fundamentals ratios updated end of day